German SME specializing in nanoparticle formulation, GMP manufacturing, and nose-to-brain drug delivery systems for nanopharmaceutical development.
MyBiotech is a German SME specializing in the formulation and GMP manufacturing of polymeric nanoparticles and microparticles for pharmaceutical applications. Their core business is developing drug delivery systems — particularly for nose-to-brain delivery of biopharmaceuticals like antibodies — and scaling these formulations from lab bench to production-ready processes. They provide galenic development, process analytical technology (PAT), and particle engineering services to research consortia developing advanced nanomedicines. The company bridges the gap between academic nanoparticle research and industrial-scale pharmaceutical production.
Central role in N2B-patch (hydrogel matrix, scale-up, GMP), Bio2Brain (formulation, particles), Phoenix (pharmaceutical open innovation test bed), nTRACK (core-shell nanoparticles), and NANOSTEM (nanomaterials for drug delivery).
N2B-patch and Bio2Brain both focus on intranasal delivery of antibodies (mAb, IgG) to the central nervous system via the olfactory region.
nTRACK included nanosafety work, CompSafeNano focuses on nanoinformatics and safe-by-design approaches, and NanoCarb explored bionano interactions and protein corona effects.
NanoCarb focused on glycan-functionalized nanoparticles, and iFermenter involved sugar conversion and biorefinery streams.
N2B-patch explicitly covered scale-up and PAT, Phoenix addresses pharmaceutical open innovation test beds, and Bio2Brain involves numerical simulation of delivery processes.
MyBiotech's early H2020 work (2017–2018) centered on hands-on particle engineering: developing multifunctional nanoparticles with specific polymer matrices (PLGA, chitosan, hyaluronic acid), GMP manufacturing processes, and scale-up for the N2B-patch nose-to-brain project. In the later period (2021 onward), they shifted toward more systematic and digital approaches — nanoinformatics, safe-by-design frameworks (CompSafeNano), pharmaceutical test bed infrastructure (Phoenix), and computational simulation of delivery processes (Bio2Brain). The trajectory shows a company moving from pure formulation services toward becoming a platform provider for nanopharmaceutical development and safety assessment.
MyBiotech is evolving from a contract nanoparticle manufacturer into a more integrated nanopharmaceutical development partner, adding digital tools (nanoinformatics, simulation) and safety-by-design capabilities to their formulation expertise.
MyBiotech consistently operates as a specialized technical partner — they have never coordinated an H2020 project, instead contributing specific formulation and manufacturing expertise to larger consortia. With 98 unique partners across 31 countries, they are well-networked and comfortable working in diverse international teams. Their participation in both Marie Curie training networks (3 MSCA projects) and large innovation actions suggests they are valued both as an industrial training host and as a scale-up partner who can take academic nanoparticle concepts toward production readiness.
Exceptionally broad network for an SME: 98 unique consortium partners across 31 countries, indicating they are a sought-after specialist that different research groups invite into their proposals. Their network spans Western and Southern Europe heavily, consistent with strong ties to nanomedicine research hubs in France, Spain, Italy, and the Nordic countries.
MyBiotech occupies a rare niche as an SME that can take nanoparticle formulations from concept through GMP-compliant manufacturing — a capability gap that many academic consortia need but few small companies can fill. Their combined expertise in polymer-based drug delivery, intranasal administration routes, and process analytical technology makes them a natural partner for any consortium developing nanomedicines that need to reach clinical-grade production. For consortium builders, they offer industrial credibility and manufacturing know-how without the overhead or IP complications of partnering with a large pharma company.
